Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Significance of serum-soluble CD95 (Fas/APO-1) on prognosis in renal cell cancer patients.

Literature DB >> 10408413

Significance of serum-soluble CD95 (Fas/APO-1) on prognosis in renal cell cancer patients.

M Kimura¹, Y Tomita, T Imai, T Saito, A Katagiri, T Tanikawa, M Takeda, K Takahashi.

Abstract

Serum-soluble CD95 (sCD95) levels for 72 renal cell cancer patients were significantly higher than those of 17 healthy donors. Twenty-one of 72 patients had elevated (defined as more than mean of healthy donors + 2 s.d.) sCD95. The disease-specific survival rate was significantly lower in the elevated sCD95 group. Serum sCD95 level was shown to be an independent prognostic factor by univariate and multivariate analysis, indicating a possible significant role in determining treatment strategies.

Entities: Disease Gene Species

Mesh：

Substances：
fas Receptor

Year: 1999 PMID： 10408413 PMCID： PMC2363168 DOI： 10.1038/sj.bjc.6690576

Source DB: PubMed Journal: Br J Cancer ISSN： 0007-0920 Impact factor: 7.640

14 in total

Review 1. Fas and Fas ligand: a death factor and its receptor.

Authors: S Nagata
Journal: Adv Immunol Date: 1994 Impact factor: 3.543

2. Biologically active Fas antigen and its cognate ligand are expressed on plasma membrane-derived extracellular vesicles.

Authors: J Albanese; S Meterissian; M Kontogiannea; C Dubreuil; A Hand; S Sorba; N Dainiak
Journal: Blood Date: 1998-05-15 Impact factor: 22.113

3. Tetrapeptide DEVD-aldehyde or YVAD-chloromethylketone inhibits Fas/Apo-1(CD95)-mediated apoptosis in renal-cell-cancer cells.

Authors: Y Tomita; T Kawasaki; V Bilim; M Takeda; K Takahashi
Journal: Int J Cancer Date: 1996-09-27 Impact factor: 7.396

4. CD28 costimulation can promote T cell survival by enhancing the expression of Bcl-XL.

Authors: L H Boise; A J Minn; P J Noel; C H June; M A Accavitti; T Lindsten; C B Thompson
Journal: Immunity Date: 1995-07 Impact factor: 31.745

Review 5. Prognostic factors in renal cell carcinoma.

Authors: D Lanigan
Journal: Br J Urol Date: 1995-05

6. Elevated soluble Fas (sFas) levels in nonhematopoietic human malignancy.

Authors: G P Midis; Y Shen; L B Owen-Schaub
Journal: Cancer Res Date: 1996-09-01 Impact factor: 12.701

7. Fas/APO-1-mediated apoptosis of human renal cell carcinoma.

Authors: N Nonomura; T Miki; M Yokoyama; T Imazu; T Takada; S Takeuchi; N Kanno; K Nishimura; Y Kojima; A Okuyama
Journal: Biochem Biophys Res Commun Date: 1996-12-24 Impact factor: 3.575

8. Soluble Fas/APO-1 in tumor cells: a potential regulator of apoptosis?

Authors: L B Owen-Schaub; L S Angelo; R Radinsky; C F Ware; T G Gesner; D P Bartos
Journal: Cancer Lett Date: 1995-07-20 Impact factor: 8.679

9. Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule.

Authors: J Cheng; T Zhou; C Liu; J P Shapiro; M J Brauer; M C Kiefer; P J Barr; J D Mountz
Journal: Science Date: 1994-03-25 Impact factor: 47.728

10. Identification of soluble APO-1 in supernatants of human B- and T-cell lines and increased serum levels in B- and T-cell leukemias.

Authors: E Knipping; K M Debatin; K Stricker; B Heilig; A Eder; P H Krammer
Journal: Blood Date: 1995-03-15 Impact factor: 22.113

4 in total

Review 1. Basic research in kidney cancer.

Authors: Egbert Oosterwijk; W Kimryn Rathmell; Kerstin Junker; A Rose Brannon; Frédéric Pouliot; David S Finley; Peter F A Mulders; Ziya Kirkali; Hirotsugo Uemura; Arie Belldegrun
Journal: Eur Urol Date: 2011-07-05 Impact factor: 20.096